JP2022534788A - Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 - Google Patents
Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 Download PDFInfo
- Publication number
- JP2022534788A JP2022534788A JP2021571896A JP2021571896A JP2022534788A JP 2022534788 A JP2022534788 A JP 2022534788A JP 2021571896 A JP2021571896 A JP 2021571896A JP 2021571896 A JP2021571896 A JP 2021571896A JP 2022534788 A JP2022534788 A JP 2022534788A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- crystalline form
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025101917A JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858837P | 2019-06-07 | 2019-06-07 | |
| US62/858,837 | 2019-06-07 | ||
| PCT/US2020/036137 WO2020247643A1 (en) | 2019-06-07 | 2020-06-04 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101917A Division JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534788A true JP2022534788A (ja) | 2022-08-03 |
| JP2022534788A5 JP2022534788A5 (cg-RX-API-DMAC7.html) | 2023-06-07 |
Family
ID=71787182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571896A Pending JP2022534788A (ja) | 2019-06-07 | 2020-06-04 | Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 |
| JP2025101917A Pending JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101917A Pending JP2025138706A (ja) | 2019-06-07 | 2025-06-18 | Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのcb1拮抗薬 |
| JP2013502424A (ja) * | 2009-08-17 | 2013-01-24 | メモリアル スローン−ケタリング キャンサー センター | 熱ショックタンパク質結合化合物、組成物、およびそれらを製造するための方法 |
| WO2015107493A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| WO2015107495A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
| WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| KR20200143417A (ko) | 2018-04-10 | 2020-12-23 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
-
2020
- 2020-06-04 CA CA3142430A patent/CA3142430A1/en active Pending
- 2020-06-04 EP EP20746488.4A patent/EP3980128A1/en active Pending
- 2020-06-04 CN CN202080054905.0A patent/CN114190090A/zh active Pending
- 2020-06-04 MX MX2021014855A patent/MX2021014855A/es unknown
- 2020-06-04 PH PH1/2021/552902A patent/PH12021552902A1/en unknown
- 2020-06-04 KR KR1020227000184A patent/KR20220019017A/ko not_active Ceased
- 2020-06-04 TW TW109118750A patent/TW202112785A/zh unknown
- 2020-06-04 BR BR112021022635A patent/BR112021022635A2/pt not_active IP Right Cessation
- 2020-06-04 AU AU2020288631A patent/AU2020288631A1/en not_active Abandoned
- 2020-06-04 CN CN202210564150.XA patent/CN115141205A/zh active Pending
- 2020-06-04 MA MA056113A patent/MA56113A/fr unknown
- 2020-06-04 SG SG11202112461QA patent/SG11202112461QA/en unknown
- 2020-06-04 JP JP2021571896A patent/JP2022534788A/ja active Pending
- 2020-06-04 WO PCT/US2020/036137 patent/WO2020247643A1/en not_active Ceased
-
2021
- 2021-02-26 US US17/187,504 patent/US11220501B2/en active Active
- 2021-11-29 US US17/537,113 patent/US12528807B2/en active Active
- 2021-12-01 IL IL288568A patent/IL288568A/en unknown
-
2025
- 2025-06-18 JP JP2025101917A patent/JP2025138706A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536950A (ja) * | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのcb1拮抗薬 |
| JP2013502424A (ja) * | 2009-08-17 | 2013-01-24 | メモリアル スローン−ケタリング キャンサー センター | 熱ショックタンパク質結合化合物、組成物、およびそれらを製造するための方法 |
| WO2015107493A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| WO2015107495A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
| WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Non-Patent Citations (5)
| Title |
|---|
| 厚生労働省医薬局審査管理課長: "安定性試験ガイドラインの改定について", 医薬審発第0603001号, JPN6023001926, 3 June 2003 (2003-06-03), pages 1 - 24, ISSN: 0005645468 * |
| 平山 令明, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6021045084, 2008, pages 36 - 43, ISSN: 0005322816 * |
| 芦澤 一英 他, 医薬品の多形現象と晶析の科学, JPN7015003233, 20 September 2002 (2002-09-20), pages 305 - 317, ISSN: 0005322814 * |
| 芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005322817 * |
| 長瀬 博, 最新 創薬化学 下巻, JPN6016015442, 1999, pages 347 - 354, ISSN: 0005322815 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MA56113A (fr) | 2022-04-13 |
| US12528807B2 (en) | 2026-01-20 |
| TW202112785A (zh) | 2021-04-01 |
| MX2021014855A (es) | 2022-01-18 |
| CN115141205A (zh) | 2022-10-04 |
| EP3980128A1 (en) | 2022-04-13 |
| IL288568A (en) | 2022-02-01 |
| AU2020288631A1 (en) | 2021-12-09 |
| BR112021022635A2 (pt) | 2022-01-04 |
| JP2025138706A (ja) | 2025-09-25 |
| PH12021552902A1 (en) | 2022-04-04 |
| US11220501B2 (en) | 2022-01-11 |
| CN114190090A (zh) | 2022-03-15 |
| WO2020247643A1 (en) | 2020-12-10 |
| KR20220019017A (ko) | 2022-02-15 |
| CA3142430A1 (en) | 2020-12-10 |
| US20210253574A1 (en) | 2021-08-19 |
| SG11202112461QA (en) | 2021-12-30 |
| US20220298159A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025138706A (ja) | Shp2阻害物質である{6-[(2-アミノ-3-クロロピリジン-4-イル)スルファニル]-3-[(3s,4s)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-メチルピラジン-2-イル}メタノールの固体形態 | |
| JP7092935B2 (ja) | 固体形態 | |
| CA3098336C (en) | Crystal form of c-met inhibitor and salt form thereof and preparation method therefor | |
| US9012464B2 (en) | Salts and polymorphic forms of Afatinib | |
| JP2025131597A (ja) | 固体形態 | |
| US20230167128A1 (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
| TW201800413A (zh) | 作為jak抑制劑的吡咯並嘧啶化合物的結晶 | |
| EA015677B1 (ru) | СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА | |
| WO2014016848A2 (en) | Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof | |
| JP2023549572A (ja) | Fgfr阻害剤、ならびにこれを作製および使用する方法 | |
| IL302520A (en) | Morphic forms of hexadecyloxypropyl-phosphonate esters | |
| WO2016090257A1 (en) | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) | |
| JP2020534331A (ja) | ((1s,2s,4r)−4−{4−[(1s)−2,3−ジヒドロ−1h−インデン−1−イルアミノ]−7h−ピロロ[2,3−d]ピリミジン−7−イル}−2−ヒドロキシシクロペンチル)メチルスルファメートの共結晶形態、その製剤及び使用 | |
| TW202039511A (zh) | Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物 | |
| HK40077975A (zh) | Shp2抑制剂的固体形式 | |
| JP2025518579A (ja) | Irak4阻害剤としてのヘテロシクリルアミドの固体形態 | |
| HK40068870A (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor | |
| WO2022242753A1 (zh) | 一种吡唑并杂芳基类衍生物的可药用盐及其结晶形式 | |
| US10072029B2 (en) | Crystalline form of a proteasome inhibitor | |
| WO2014147641A2 (en) | Sitagliptin pterostilbene phosphate salt, process for the preparation and pharmaceutical composition thereof | |
| TW202340184A (zh) | Cdk9抑制劑的多晶型物及其製法和用途 | |
| TW202220983A (zh) | Cdk9抑制劑的多晶型物及其製法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230530 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240514 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240516 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241113 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250618 |